Healthcare providers should advise patients on strategies to ensure medication adherence and continuity. Plans should be in place and ample supplies should be available to address any potential shortages or needs for rescue therapies.
If feasible, providers might consider writing 90-day rather than 30-day supplies of medications.
COVID-19 Vaccine Information
Antiseizure Medications (ASMs)
- AES Clinical Corner: Paxlovid™, AES, February 25, 2022
- Paxlovid™ Information from FDA and Guidance for AES Members, AES, February 1, 2022
- Managing Patients with Epilepsy during COVID-19 - Pharmacotherapy-related Recommendations, AES, April 9, 2020
- Effective Engagement of Pharmacists During COVID-19 and Beyond, AES, April 9, 2020
- AES Comments on Therapeutic Substitution of Medications, April 3, 2020 [PDF]
- FDA updates on a range of COVID-related Center for Drug Evaluation and Research Resources
- Not your usual drug-drug interactions: Monoclonal antibody-based therapeutics may interact with antiseizure medications